BioHarvest Sciences

BHST

Market cap $118M

BioHarvest Sciences Inc. (NASDAQ:BHST) has launched VINIA Blood Hydration, a new electrolyte product that incorporates the company's Piceid resveratrol ingredient. The launch marks BioHarvest's entry into the US hydration and electrolyte category, a market the company cites as worth about $13 billion.

First Hydration Formula Powered by VINIA's Blood Flow Technology Enters the $13 Billion U.S. Electrolyte Market Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - December 3, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology platform, announces the U.S. launch of VINIA Blood Flow Hydration™, the first hydration solution powered by the blood flow benefits of VINIA's Piceid resveratrol to enter the $13 Billion US Electrolytes Drink Market*. Better Hydration Starts with Better Blood Flow Following overwhelmingly positive early-adopter interest, VINIA Blood Flow Hydration™ is now shipping nationwide and is available exclusively at Vinia.com, with free delivery across North America.

BioHarvest Sciences Inc. ( BHST ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Ilan Sobel - Chief Executive Officer Bar Dichter - Chief Financial Officer Conference Call Participants Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division Nicholas Sherwood - Maxim Group LLC, Research Division Susan Anderson - Canaccord Genuity Corp., Research Division Presentation Operator Greetings, and welcome to the BioHarvest Sciences Third Quarter 2025 Corporate Update Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.16 per share a year ago.

BioHarvest Sciences Inc. (NASDAQ:BHST), a biotechnology company known for its patented Botanical Synthesis technology, reported a 39% increase in third-quarter revenue, driven by growth in its core VINIA capsule business and expanding contract development and manufacturing (CDMO) operations. Total revenues for the quarter ended September 30 rose to $9.1 million, in line with management guidance.

Strong VINIA Momentum and New CDMO Win Delivers 39% Year-Over-Year Growth Company Fortifies Balance Sheet with Recent $19.9 Million Instiutional Equity Raise Following $14.7 Million Strengthening of Balance Sheet via Accelerated Warrant Exercises and Debt-to-Equity Conversions in September Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 13, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a biotechnology company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the third quarter ended September 30, 2025. Third Quarter 2025 Operational Highlights All figures stated in this news release are in U.S. dollars unless stated otherwise.

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 12, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that management has been invited to attend the Craig-Hallum 16th Annual Alpha Select Conference taking place on Tuesday, November 18th, 2025 in New York, NY. CEO Ilan Sobel is scheduled to host one-on-one meetings with institutional investors throughout the event as shown below.

BioHarvest Sciences Inc. (NASDAQ:BHST), a company developing its patented Botanical Synthesis technology platform, said on Monday it has completed an underwritten public offering of 2.85 million shares of common stock at $7 per share, generating gross proceeds of $19.9 million. The company said it plans to use the net proceeds for manufacturing expansion, research and development, marketing, debt reduction or refinancing, other capital expenditures, and general corporate purposes, including working capital.

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 10, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology platform, announces the closing of its previously announced underwritten public offering of 2,846,854 shares of common stock, no par value, and at a public offering price of $7.00 per share, which includes 361,854 shares issued upon the exercise by the underwriters of their option to purchase additional shares of common stock in the offering. The gross proceeds from this offering were $19.9 million, before deducting the underwriting discount and other offering expenses.

BioHarvest Sciences Inc. (NASDAQ:BHST) announced that it has priced its underwritten public offering of 2,485,000 company shares at $7.00 per share, for expected gross proceeds of about $17.4 million.  The company said it expects to use the net proceeds from the offering for research and development, manufacturing, marketing, advancing the CDMO business unit, debt reduction or debt refinancing, capital expenditures, and general corporate purposes, including funding working capital.